
Compartir
Título
The role of GAB1 in cancer
Autor(es)
Palabras clave
GAB1
angiogenesis
metastasis
therapy resistance
tumorigenesis
Clasificación UNESCO
3209 Farmacología
Fecha de publicación
2023-08-20
Editor
MDPI
Citación
Pérez-Baena, M. J., Cordero-Pérez, F. J., Pérez-Losada, J., & Holgado-Madruga, M. (2023). The role of GAB1 in cancer. Cancers, 15(16), 4179.
Resumen
[EN]GRB2-associated binder 1 (GAB1) is the inaugural member of the GAB/DOS family of pleckstrin homology (PH) domain-containing proteins. Upon receiving various stimuli, GAB1 transitions from the cytoplasm to the membrane where it is phosphorylated by a range of kinases. This event recruits SH2 domain-containing proteins like SHP2, PI3K's p85 subunit, CRK, and others, thereby activating distinct signaling pathways, including MAPK, PI3K/AKT, and JNK. GAB1-deficient embryos succumb in utero, presenting with developmental abnormalities in the heart, placenta, liver, skin, limb, and diaphragm myocytes. Oncogenic mutations have been identified in the context of cancer. GAB1 expression levels are disrupted in various tumors, and elevated levels in patients often portend a worse prognosis in multiple cancer types. This review focuses on GAB1's influence on cellular transformation particularly in proliferation, evasion of apoptosis, metastasis, and angiogenesis-each of these processes being a cancer hallmark. GAB1 also modulates the resistance/sensitivity to antitumor therapies, making it a promising target for future anticancer strategies.
URI
DOI
10.3390/cancers15164179
Versión del editor
Aparece en las colecciones













